AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17240222 — intervention group
Group type: COMPARATOR
Intervention: Curettage
Number of subjects: 652
Study 15876453 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-containing compomer (TC)
Number of subjects: 30
Study 15876453 — intervention group
Group type: EXPERIMENTAL
Intervention: 36% phosphoric acid (PH) for 15s
Number of subjects: 30
Study 15876453 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control - CO)
Number of subjects: 30
Study 12476540 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide HFA 85 micrograms
Number of subjects: 21
Study 12476540 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide HFA 170 micrograms
Number of subjects: 21
Study 12476540 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide HFA 340 micrograms
Number of subjects: 21
Study 12476540 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide HFA (all doses)
Number of subjects: 21
Study 12476540 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 beta‐OH flunisolide (inactive metabolite)
Number of subjects: 21
Study 9596204 — intervention group
Group type: EXPERIMENTAL
Intervention: Teril 400 CR
Number of subjects: 0
Study 9596204 — intervention group
Group type: COMPARATOR
Intervention: Tegretol CR Divitab
Number of subjects: 0
Study 8169675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rapid infusion of indomethacin
Number of subjects: 19
Study 8169675 — intervention group
Group type: COMPARATOR
Intervention: Intravenous slow infusion of indomethacin
Number of subjects: 19
Study 29120039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostin 15M 250 microg intramuscular injection every two hours until 1 cm cervical dilation, then every three hours until abortion.
Number of subjects: 322
Study 29120039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic loperamide and emidoxyn given in 53 cases.
Number of subjects: 322
Study 29120039 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood loss measured by alkaline hematin method in 50 cases.
Number of subjects: 322
Study 30145595 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL training
Number of subjects: 87
Study 30145595 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 87
Study 30145595 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined multicomponent exercise and ADL training
Number of subjects: 87
Study 30145595 — intervention group
Group type: COMPARATOR
Intervention: No physical stimulation
Number of subjects: 87
Study 28148280 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab and methotrexate combination treatment
Number of subjects: 36
Study 28148280 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab monotherapy
Number of subjects: 36
Study 26036774 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) in patients with known OSA (66/94, 70%)
Number of subjects: 247
Study 26036774 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) in patients with high risk STOP-BANG scores (95/124, 77%)
Number of subjects: 247
Study 26036774 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) in patients with low risk OSA scores (29/32, 91%)
Number of subjects: 247
Study 26036774 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk STOP-BANG score predicting recurrent AF in patients without prior OSA diagnosis
Number of subjects: 247
Study 26036774 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-paroxysmal AF patients
Number of subjects: 247
Study 24107880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantocalcin (hopantenic acid preparation)
Number of subjects: 0
Study 24107880 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 21924414 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-hCG group
Number of subjects: 120
Study 21924414 — intervention group
Group type: COMPARATOR
Intervention: Late-hCG group
Number of subjects: 120
Study 19033842 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic endonasal surgery simulator training
Number of subjects: 15
Study 19033842 — intervention group
Group type: COMPARATOR
Intervention: Control group (no simulator training)
Number of subjects: 15
Study 16990670 — intervention group
Group type: EXPERIMENTAL
Intervention: Single reading with computer-aided detection (CAD)
Number of subjects: 10267
Study 16990670 — intervention group
Group type: COMPARATOR
Intervention: Double reading
Number of subjects: 10267
Study 14656361 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartrazine (5 mg)
Number of subjects: 102
Study 14656361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 14656361 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE tests for food allergy
Number of subjects: 102
Study 10759359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg bid
Number of subjects: 490
Study 10759359 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 50,000 IU given in three divided doses
Number of subjects: 490
Study 8823889 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ear (right hemisphere)
Number of subjects: 139
Study 8823889 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ear (left hemisphere)
Number of subjects: 139
Study 8823889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ears (combined hemispheres)
Number of subjects: 139
Study 1295136 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine therapy (25 mg base/kg over 3 days)
Number of subjects: 109
Study 6203285 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-butyryl dithranol (butantrone)
Number of subjects: 17
Study 6203285 — intervention group
Group type: EXPERIMENTAL
Intervention: dithranol, 10-propionyl dithranol, 10-butyryl dithranol
Number of subjects: 17
Study 29308849 — intervention group
Group type: EXPERIMENTAL
Intervention: Overloaded 10‐second cycling PAP protocol followed by a Wingate Test at 10 minutes post-PAP
Number of subjects: 20
Study 29308849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestpeak‐P condition (peak power output)
Number of subjects: 20
Study 29308849 — intervention group
Group type: COMPARATOR
Intervention: Control session (sub‐maximal cycling warm-up followed by a Wingate Test)
Number of subjects: 20
Study 30209862 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 0
Study 30209862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27776079 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level continuous heat (LLCH) wraps applied for 6 hours at home before home exercise
Number of subjects: 50
Study 27776079 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level continuous heat (LLCH) wraps
Number of subjects: 50
Study 27776079 — intervention group
Group type: COMPARATOR
Intervention: Placebo ibuprofen
Number of subjects: 50
Study 24916520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Number of subjects: 0
Study 24916520 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 22280484 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education and multimodal physiotherapy (including neuromuscular training and home exercises)
Number of subjects: 102
Study 22280484 — intervention group
Group type: COMPARATOR
Intervention: Patient education (written information and general advice)
Number of subjects: 102
Study 21198234 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference work
Number of subjects: 49
Study 21198234 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 49
Study 21198234 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference work with lower therapeutic alliance ratings
Number of subjects: 49
Study 21198234 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of transference work
Number of subjects: 49
Study 17413101 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Load (HG) diet at 30% calorie restriction (CR)
Number of subjects: 34
Study 17413101 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Load (LG) diet at 30% calorie restriction (CR)
Number of subjects: 34
Study 17413101 — intervention group
Group type: COMPARATOR
Intervention: High Glycemic Load (HG) diet
Number of subjects: 34
Study 17413101 — intervention group
Group type: COMPARATOR
Intervention: Low Glycemic Load (LG) diet
Number of subjects: 34
Study 16234005 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless capsule endoscopy (WCE)
Number of subjects: 31
Study 16234005 — intervention group
Group type: COMPARATOR
Intervention: Enteroclysis
Number of subjects: 31
Study 12140795 — intervention group
Group type: EXPERIMENTAL
Intervention: RC-Cornet(R) therapy group (combined-PEP therapy)
Number of subjects: 50
Study 12140795 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy group (theophylline, salmeterol, ipratropiumbromide, systemic steroids)
Number of subjects: 50
Study 10430331 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg/week, adjusted up to 22.5 mg/week
Number of subjects: 33
Study 10430331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 10430331 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 33
Study 10430331 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and Placebo
Number of subjects: 33
Study 7563988 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt task‐oriented verbalization
Number of subjects: 120
Study 7563988 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert task‐oriented verbalization
Number of subjects: 120
Study 7563988 — intervention group
Group type: COMPARATOR
Intervention: No verbalization
Number of subjects: 120
Study 2250563 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (CT) 100 UI administered by intravenous route
Number of subjects: 10
Study 2250563 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (CT) 100 UI administered by intramuscular route
Number of subjects: 10
Study 2250563 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (CT) 100 UI administered by nasal route
Number of subjects: 10
Study 2250563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7282732 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg every 6 hours and 80 mg every 6 hours)
Number of subjects: 18
Study 7282732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Verapamil (120 mg every 6 hours)
Number of subjects: 18
Study 7282732 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and High-dose Verapamil
Number of subjects: 18
Study 7282732 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 18
Study 7282732 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 18
Study 31596127 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial pancreas with learning algorithm (daily updates of basal rates and carbohydrate ratios)
Number of subjects: 34
Study 31596127 — intervention group
Group type: COMPARATOR
Intervention: Artificial pancreas alone (no learning algorithm)
Number of subjects: 34
Study 30836685 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency + self-selected timing (HST)
Number of subjects: 69
Study 30836685 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency + self-selected timing (LST)
Number of subjects: 69
Study 30836685 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency + assigned timing (HAT)
Number of subjects: 69
Study 30836685 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency + assigned timing (LAT)
Number of subjects: 69
Study 30836685 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 28385473 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive 6-day culture
Number of subjects: 299
Study 28385473 — intervention group
Group type: COMPARATOR
Intervention: Negative 6-day culture
Number of subjects: 299
Study 25885862 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders at 6, 10, and 14 weeks in addition to routine health education
Number of subjects: 304
Study 25885862 — intervention group
Group type: COMPARATOR
Intervention: Routine health education without SMS reminders
Number of subjects: 304
Study 25885862 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 304
Study 24081011 — intervention group
Group type: EXPERIMENTAL
Intervention: Test of Infant Motor Performance (TIMP)
Number of subjects: 145
Study 24081011 — intervention group
Group type: COMPARATOR
Intervention: Bayley Motor scale
Number of subjects: 145
Study 21493943 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive support including fees, uniforms, and a school-based helper
Number of subjects: 329
Study 19781466 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsional ultrasound mode
Number of subjects: 400
Study 19781466 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal ultrasound mode
Number of subjects: 400
Study 16440428 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG)
Number of subjects: 36
Study 16440428 — intervention group
Group type: COMPARATOR
Intervention: Non-PEG group
Number of subjects: 36
Study 16440428 — intervention group
Group type: COMPARATOR
Intervention: Control group (ventilated patients without reflux)
Number of subjects: 36
Study 15497780 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10778882 — intervention group
Group type: EXPERIMENTAL
Intervention: Test diet with soy protein foods (33 g/d soy protein)
Number of subjects: 31
Study 10778882 — intervention group
Group type: EXPERIMENTAL
Intervention: Test diet with soy protein foods
Number of subjects: 31
Study 10778882 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 31
Study 9068332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80
Study 9068332 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 80
Study 7870896 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (75 mg daily)
Number of subjects: 14
Study 7870896 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol infusion
Number of subjects: 14
Study 3530865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg at bedtime for 6 months)
Number of subjects: 108
Study 3530865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 3530865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (open treatment)
Number of subjects: 108
Study 30940400 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone monitoring with CrossCheck behavioral sensing system
Number of subjects: 61
Study 29177440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of adjuvant sorafenib
Number of subjects: 233
Study 29177440 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 years of adjuvant sorafenib
Number of subjects: 233
Study 29177440 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no adjuvant therapy)
Number of subjects: 233
Study 26308112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaqta/Infanrix PedvaxHIB on Day‐1 and Vaqta at Week‐24
Number of subjects: 0
Study 26308112 — intervention group
Group type: EXPERIMENTAL
Intervention: Infanrix PedvaxHIB on Day‐1, Vaqta at Week‐4, and Vaqta at Week‐28
Number of subjects: 0
Study 26308112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaqta/PedvaxHIB on Day‐1 and Vaqta Week‐24
Number of subjects: 0
Study 26308112 — intervention group
Group type: EXPERIMENTAL
Intervention: PedvaxHIB on Day‐1, Vaqta at Week‐4, and Vaqta at Week‐28
Number of subjects: 0
Study 26308112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaqta on Day‐1 and Vaqta at Week‐24 (safety only)
Number of subjects: 0
Study 26308112 — intervention group
Group type: COMPARATOR
Intervention: Groups 1-4 (concomitant administration)
Number of subjects: 0
Study 26308112 — intervention group
Group type: COMPARATOR
Intervention: Concomitant administration of Vaqta, PedvaxHIB, and Infanrix
Number of subjects: 0
Study 26308112 — intervention group
Group type: COMPARATOR
Intervention: Concomitant vs nonconcomitant groups
Number of subjects: 0
Study 26308112 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration
Number of subjects: 0
Study 25473191 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone (Amitza), orally twice a day for six days
Number of subjects: 64
Study 25473191 — intervention group
Group type: COMPARATOR
Intervention: Senna (generic), two capsules daily for six days
Number of subjects: 64
Study 25473191 — intervention group
Group type: COMPARATOR
Intervention: Senna (generic)
Number of subjects: 64
Study 25473191 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lubiprostone and Senna
Number of subjects: 64
Study 22901344 — intervention group
Group type: EXPERIMENTAL
Intervention: Raise end-tidal P(CO₂) group
Number of subjects: 74
Study 22901344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower end-tidal P(CO₂) group
Number of subjects: 74
Study 22901344 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 74
Study 20848932 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoinduction active material (OAM)
Number of subjects: 27
Study 20848932 — intervention group
Group type: COMPARATOR
Intervention: Autogenous ilium cancellous bone
Number of subjects: 27
Study 20848932 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM
Number of subjects: 27
Study 17957158 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat treatment
Number of subjects: 16
Study 17957158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15878095 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy in 25 fractions (F)
Number of subjects: 1410
Study 15878095 — intervention group
Group type: EXPERIMENTAL
Intervention: 39 Gy in 13 F
Number of subjects: 1410
Study 15878095 — intervention group
Group type: EXPERIMENTAL
Intervention: 42.9 Gy in 13 F
Number of subjects: 1410
Study 15878095 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy in 25 F
Number of subjects: 1410
Study 11952580 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy (6 MIU intramuscularly every day for 2 weeks, then three times a week for 14 weeks and finally twice a week for 88 weeks)
Number of subjects: 30
Study 11952580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study 11952580 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy
Number of subjects: 30
Study 11952580 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 9605029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Group 2) received 2 books and educational materials.
Number of subjects: 151
Study 9605029 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1) did not receive books or educational materials.
Number of subjects: 151
Study 7698517 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide (2.5 mg/day)
Number of subjects: 30
Study 7698517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7698517 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study 2744191 — intervention group
Group type: EXPERIMENTAL
Intervention: TDT catheter (Prodimed, Neuilly‐en‐Thelle, France)
Number of subjects: 400
Study 2744191 — intervention group
Group type: EXPERIMENTAL
Intervention: TDT catheter (Prodimed, Neuilly‐en‐Thelle, France) under ultrasound guidance
Number of subjects: 400
Study 2744191 — intervention group
Group type: EXPERIMENTAL
Intervention: Frydman catheter (Prodimed, Neuilly‐en‐Thelle, France)
Number of subjects: 400
Study 2744191 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallace catheter (H.G. Wallace Limited, Colchester, England)
Number of subjects: 400
Study 792893 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate
Number of subjects: 0
Study 792893 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine hydrochloride
Number of subjects: 0
Study 30833149 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) filler injection
Number of subjects: 72
Study 30833149 — intervention group
Group type: COMPARATOR
Intervention: Polylactic Acid (PLA) filler injection
Number of subjects: 72
Study 28286061 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab for 52 weeks
Number of subjects: 107
Study 28286061 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks followed by adalimumab for 52 weeks
Number of subjects: 107
Study 25761731 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-limited group (FL)
Number of subjects: 14
Study 25761731 — intervention group
Group type: COMPARATOR
Intervention: Non-flow-limited group (non-FL)
Number of subjects: 14
Study 23305820 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step facilitation for stimulant abusers
Number of subjects: 182
Study 23305820 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS‐11 motor score
Number of subjects: 182
Study 23305820 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS‐11 non‐planning and total scores
Number of subjects: 182
Study 23305820 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop interference scores
Number of subjects: 182
Study 21969930 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 250 mcg twice daily for four weeks
Number of subjects: 12
Study 21969930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21969930 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label treatment with fluticasone propionate 250 mcg/salmeterol 50 mcg
Number of subjects: 12
Study 18524134 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) solutions (light, medium, heavy molecular weight)
Number of subjects: 29
Study 18524134 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 29
Study 18524134 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of platelet activating factor IV (PAF IV)
Number of subjects: 29
Study 16336479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal thermal annuloplasty (IDTA)
Number of subjects: 42
Study 16336479 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency annuloplasty (RFA)
Number of subjects: 42
Study 12014900 — intervention group
Group type: EXPERIMENTAL
Intervention: HW with non-antiseptic soap for 10 seconds (US10)
Number of subjects: 43